Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 26, 2024 (Event Date)
Reporting Period: Specific transaction date of July 26, 2024, with agreements dated July 28, 2024.
Key Financial Metrics and Transaction Details
This filing reports a private placement and strategic investment rather than standard periodic financial results (revenue, profit, or cash flow statements are not included in this 8-K).
- Private Placement Proceeds: $1,000,000 aggregate purchase price.
- Common Stock Issued: 698,812 shares at $1.431 per share (90% of July 22, 2024 closing price).
- Warrants Issued: 600,000 warrants exercisable at $1.90 per share (120% of July 22, 2024 closing price), expiring July 28, 2027.
- Strategic Investment in Subsidiary: Approximately $2,000,000 invested by Dr. Ronald Rigor into Nova Cell, Inc. (a subsidiary).
- Subsidiary Equity: Investment results in issuance of 7,500,000 Nova Cell shares, representing 25% of Nova Cell's fully-diluted capitalization.
Material Changes and Agreements
The filing details three primary material agreements entered into on July 26-28, 2024:
- Subscription Agreement: Sale of equity and warrants to accredited investor Dr. Ronald Rigor.
- SMAB Appointment: Dr. Rigor appointed to the Scientific and Medical Advisory Board. Compensation includes 5,000 stock options with a four-year vesting period.
- Intellectual Property Assignment: Assignment of certain IP rights to Nova Cell, Inc. in conjunction with the $2,000,000 investment.
Outlook, Risks, and Management Commentary
Management Commentary: The Board views Dr. Rigor's expertise in stem cell therapy as invaluable to advancing the Company's initiatives. The transaction is structured to secure capital and strategic advisory support simultaneously.
Warrant Limitations: The warrants are subject to a beneficial ownership limitation of 4.99% of the common stock outstanding immediately after exercise.
Risks and Contingencies: The filing notes that the descriptions of the agreements are qualified by the full text of the attached exhibits. No specific financial risks or contingencies regarding the company's overall liquidity are detailed in this specific report, though the capital raise implies a need for funding.
Investor Verification Checklist
- Verify the dilution impact of the 698,812 new shares and 600,000 warrants on existing shareholders.
- Confirm the specific intellectual property rights assigned to Nova Cell, Inc. via Exhibit 10.3.
- Review the full terms of the SMAB Consulting Agreement (Exhibit 10.2) regarding the 5,000 stock options.
- Assess the financial health and capitalization of Nova Cell, Inc. following the 25% equity issuance to Dr. Rigor.
- Check the press release (Exhibit 99.1) for additional context on the strategic rationale not fully detailed in the 8-K text.